BANB Stock Overview
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bachem Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 82.95 |
| 52 Week High | CHF 91.65 |
| 52 Week Low | CHF 53.95 |
| Beta | 0.69 |
| 11 Month Change | -3.32% |
| 3 Month Change | -4.27% |
| 1 Year Change | 1.78% |
| 33 Year Change | -38.46% |
| 5 Year Change | 193.73% |
| Change since IPO | 492.50% |
Recent News & Updates
Here's Why Bachem Holding (VTX:BANB) Has Caught The Eye Of Investors
Jul 23
Investors Still Waiting For A Pull Back In Bachem Holding AG (VTX:BANB)
Jun 10Recent updates
Here's Why Bachem Holding (VTX:BANB) Has Caught The Eye Of Investors
Jul 23Investors Still Waiting For A Pull Back In Bachem Holding AG (VTX:BANB)
Jun 10Here's Why Bachem Holding AG's (VTX:BANB) CEO Compensation Is The Least Of Shareholders Concerns
Apr 18Market Participants Recognise Bachem Holding AG's (VTX:BANB) Earnings Pushing Shares 40% Higher
Mar 09Investors Appear Satisfied With Bachem Holding AG's (VTX:BANB) Prospects
Dec 18We Discuss Whether Bachem Holding AG's (VTX:BANB) CEO Is Due For A Pay Rise
Apr 13Bachem Holding AG Just Missed EPS By 5.0%: Here's What Analysts Think Will Happen Next
Mar 11Is Now The Time To Look At Buying Bachem Holding AG (VTX:BANB)?
Dec 12Bachem Holding's (VTX:BANB) Solid Earnings May Rest On Weak Foundations
Sep 02I Ran A Stock Scan For Earnings Growth And Bachem Holding (VTX:BANB) Passed With Ease
May 25What You Can Learn From Bachem Holding AG's (VTX:BANB) P/E After Its 29% Share Price Crash
May 07Shareholder Returns
| BANB | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | 3.6% | 1.1% | 1.3% |
| 1Y | 1.8% | 11.4% | 7.9% |
Return vs Industry: BANB underperformed the Swiss Life Sciences industry which returned 13.9% over the past year.
Return vs Market: BANB underperformed the Swiss Market which returned 8.8% over the past year.
Price Volatility
| BANB volatility | |
|---|---|
| BANB Average Weekly Movement | 4.6% |
| Life Sciences Industry Average Movement | 4.6% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.5% |
| 10% least volatile stocks in CH Market | 1.7% |
Stable Share Price: BANB has not had significant price volatility in the past 3 months.
Volatility Over Time: BANB's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 2,009 | Thomas Meier | www.bachem.com |
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services.
Bachem Holding AG Fundamentals Summary
| BANB fundamental statistics | |
|---|---|
| Market cap | CHF 6.22b |
| Earnings (TTM) | CHF 113.57m |
| Revenue (TTM) | CHF 577.77m |
54.8x
P/E Ratio10.8x
P/S RatioIs BANB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BANB income statement (TTM) | |
|---|---|
| Revenue | CHF 577.77m |
| Cost of Revenue | CHF 398.41m |
| Gross Profit | CHF 179.36m |
| Other Expenses | CHF 65.79m |
| Earnings | CHF 113.57m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | 1.51 |
| Gross Margin | 31.04% |
| Net Profit Margin | 19.66% |
| Debt/Equity Ratio | 0% |
How did BANB perform over the long term?
See historical performance and comparison